[A 5 consecutive day combination of CIS platinum and bleomycin in squamous cell bronchial carcinoma (author's transl)].
Twenty patients with inoperable squamous cell carcinoma of the lung (14 previously untreated and 6 previously treated) received a combination of bleomycin and cis-platinum for 6 consecutive days every 3 or 4 weeks. Pulmonary toxicity was minimal with only one case of reversible bleomycin-induced acute interstitial pneumopathy. The response rate was 65 p.cent. Thirteen patients had an objective response, including 5 apparently complete regressions. All responders were previously untreated patients. The results are discussed in the light of pharmacokinetic and cell kinetic data, and lead to a proposal for a non-conventional combined approach in squamous cell carcinoma of the lung, hitherto relatively unresponsive to chemotherapy.
D000328:Adult; D000368:Aged; D001761:Bleomycin / Q000008:administration & dosage* / Q000009:adverse effects; D001984:Bronchial Neoplasms / Q000188:drug therapy*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D008875:Middle Aged
D001761:Bleomycin; D002945:Cisplatin
Association de platine- bléomycine, administrée sur 6 jours consécutifs dans les cancers bronchiques éidermoïdes : résultats préliminaires.